Overview of Proxym-MR

Quick Facts

Property	Description
Active ingredients	Etodolac, Thiocolchicoside
Form	Oral tablet
Pharmacological class	NSAID and Skeletal Muscle Relaxant Combination
General purpose	Relief of pain, inflammation, and muscle spasms
Origin	Synthetic (Etodolac) and Semi-synthetic derivative (Thiocolchicoside)

What Kind of Medicine is Proxym-MR and How is it Classified?

Proxym-MR is a prescription-only combination preparation, administered as an oral tablet, designed to target both inflammatory pain and associated muscle spasms. It is classified within two distinct pharmacological groups: the Non-steroidal anti-inflammatory drug (NSAID) class and the skeletal muscle relaxant class. This fixed-dose structure is clinically recognized as an effective approach for managing complex symptoms where pain and muscle tension overlap, providing a convenient solution compared to managing two separate medications.

What is Proxym-MR Made Of?

The composition of Proxym-MR features two principal active ingredients: Etodolac and Thiocolchicoside. Etodolac functions as the NSAID component, acting as a synthetic acetic acid derivative used for its anti-inflammatory and analgesic properties. The second component, Thiocolchicoside, is a semi-synthetic derivative of colchicine, which provides the muscle relaxation effect by acting on the central nervous system. The integration of the muscle relaxant is a differentiating feature for the Proxym-MR formulation, offering comprehensive relief for conditions marked by rigidity.

What is the General Purpose of This Combination?

The general purpose of this combination preparation is to achieve a synergistic effect, providing comprehensive relief from pain, inflammation, and muscle stiffness. Etodolac works by helping to stop the body's production of substances that cause pain and swelling, while Thiocolchicoside acts centrally to ease muscle contractions. This dual focus is intended to alleviate the symptoms of acute painful musculoskeletal conditions where the presence of muscle spasms compounds the underlying discomfort.

What side effects are possible with Proxym-MR?

Possible Side Effects and Safety Information

Proxym-MR is a combination medicine containing an NSAID (Etodolac) and a muscle relaxant (Thiocolchicoside). Its safety profile is characterized by risks common to these drug classes, requiring careful use and monitoring.

Common and Serious Adverse Reactions

Common side effects often involve the gastrointestinal system and Central Nervous System (CNS). These include: nausea, vomiting, heartburn, stomach pain, indigestion, diarrhea, dizziness, and sleepiness/drowsiness. The presence of drowsiness may impair the ability to drive or operate heavy machinery.

Serious and clinically significant adverse reactions documented in regulatory sources include the potential for gastrointestinal bleeding, ulceration, or perforation, which can occur without warning and may be fatal in rare cases. Other serious risks include acute renal failure, severe allergic/skin reactions (such as Stevens-Johnson syndrome), cardiovascular events (like congestive heart failure), and liver injury.

Safety Restrictions and Monitoring

Contraindications prohibit the use of Proxym-MR in patients with known hypersensitivity to the drug's components or other NSAIDs, active gastrointestinal ulcers/bleeding, severe heart failure, or severe renal/hepatic impairment.
Population-Specific Warnings: Use is generally not recommended during pregnancy, breastfeeding, or in children and adolescents. Women of childbearing potential should use adequate contraception during treatment due to the aneugenic potential of a thiocolchicoside metabolite, which is linked to potential fetal harm and impaired male fertility. The elderly require caution and close monitoring due to increased susceptibility to severe effects.
Monitoring Notes: Due to the risk of GI bleeding and cardiovascular events (e.g., stroke, heart attack), long-term use requires periodic clinical monitoring. Combining the medicine with alcohol should be avoided due to the increased risk of drowsiness and gastrointestinal bleeding.

Overdose and Emergency Response

Overdose and when to seek help

The documented overdose profile for Proxym-MR, derived from official regulatory labeling, describes manifestations that may affect the gastrointestinal (GI) and central nervous systems (CNS). Official signs of overdose may include nausea, vomiting, diarrhea, drowsiness, or stomach pain. In severe cases of overdose, the regulatory documents specify critical, life-threatening outcomes such as loss of consciousness (coma), acute renal failure, severe hepatotoxicity, and serious GI events including perforation and hemorrhage.

The profile notes that certain populations have an increased risk of severe outcomes, specifically the elderly, individuals with pre-existing renal or hepatic impairment, and patients with a history of epilepsy due to the Thiocolchicoside component’s effects.

Immediate medical attention is required for any suspected overdose. Official regulatory instructions mandate that emergency services (e.g., 911) must be contacted immediately if the affected individual has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened. Additionally, the national Poison Control Helpline should be called.

Management procedures officially focus on symptomatic and supportive treatment, as no specific antidote is known for either active component. Procedures may include the administration of activated charcoal if ingestion occurred within four hours of presentation.

Therapeutic Uses of Proxym-MR

What Proxym-MR Treats: Main Uses and Benefits

Proxym-MR is a combination medication applied in clinical settings that involve acute or unstable symptom patterns, where additional symptomatic support is needed to manage discomfort and functional limitation. It is relevant in contexts marked by increased discomfort and tension, providing supportive relief during periods of heightened physiological activity. This combination provides supportive symptom management.

It is commonly used across conditions characterized by periods of heightened symptoms, which may include discomfort associated with osteoarthritis, rheumatoid arthritis, and various acute painful musculoskeletal conditions. It helps address symptom clusters that may become intense or disruptive, such as joint pain, swelling, inflammation, muscle spasms, and physical rigidity. The combined formulation helps to ease the dual burden of pain and involuntary muscle tightness.

Proxym-MR may assist with supporting functional stability and contributes to easing the overall symptom load, particularly in scenarios like post-traumatic or post-operative discomfort. A key benefit is the reduction of symptomatic intensity, which supports the patient during difficult episodes by easing distress and contributes to improved comfort during symptomatic periods by assisting with temporary support for symptom management.

Quick Fact: Relief for Pain & Spasm
Primary Symptoms	Pain, Inflammation, Muscle Spasm
Typical Condition	Acute Musculoskeletal Conditions
Key Benefit	Supportive relief, improved comfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Proxym-MR?

Proxym-MR's eligibility is strictly defined by regulatory rules based on its two active components. The medicine is authorized only for adults and adolescents 16 years of age and older; use is not recommended in younger children.

The medicine is contraindicated (must not be used) in several absolute circumstances:

Known hypersensitivity to Etodolac, Thiocolchicoside, or any NSAID.
History of NSAID-induced asthma or allergic reactions to aspirin or other NSAIDs.
Active gastrointestinal ulcers or current bleeding.
Management of pain following Coronary Artery Bypass Graft (CABG) surgery.

The medicine is strictly contraindicated during the entire pregnancy period and while breastfeeding or lactating. Women of childbearing potential must use effective contraception throughout the treatment period.

Conditional use and close monitoring are required for specific populations. This includes older adults, due to higher risk of gastrointestinal issues, and patients with a history of epilepsy or pre-existing severe conditions such as uncontrolled heart failure or severe renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medicine is a combination of S(+) Etodolac, a non-steroidal anti-inflammatory drug (NSAID), and Thiocolchicoside, a muscle relaxant. The interaction profile is determined by the risks associated with both components.

Do Not Combine:

Other NSAIDs: Concomitant use with other non-steroidal anti-inflammatory drugs is generally not recommended due to the increased risk of gastrointestinal side effects, including bleeding or ulceration.
Alcohol: Avoid alcohol consumption. Alcohol may increase the risk of stomach bleeding and also cause excessive drowsiness or dizziness.

Medicines Requiring Caution:

Co-administration with the following drug categories requires careful monitoring due to potential for interaction:

Blood Thinners (Anticoagulants/Antiplatelets): Medicines like Warfarin or Aspirin, when combined with Etodolac, may synergistically increase the risk of serious gastrointestinal bleeding. Monitoring for signs of bleeding is essential.
Antihypertensives and Diuretics: The Etodolac component can diminish the blood pressure-lowering effect of medicines such as ACE inhibitors (e.g., Ramipril) and Diuretics (e.g., Furosemide). This may also increase the risk of kidney function deterioration, particularly in elderly or volume-depleted individuals.
Methotrexate and Lithium: Etodolac may increase the concentration of Methotrexate and Lithium in the body, potentially leading to increased toxicity.

Population-Specific Restrictions:

Women of Childbearing Potential: Due to the potential for the Thiocolchicoside component to cause chromosomal abnormalities (aneuploidy), use in women of childbearing potential is contraindicated unless effective contraception is strictly followed.

Mechanism of Action

Proxym-MR exerts its effect through a dual mechanistic domain that influences both peripheral nociceptive signaling and the central control of motor efferent pathways. This mechanism involves simultaneously acting on key enzymes in tissue and on inhibitory receptors within the central nervous system, resulting in altered physiological control within the affected systems.

One domain of action involves the inhibition of Cyclooxygenase (COX) enzymes, which are critical for the synthesis of prostaglandins—chemical mediators that sensitize peripheral nerve endings. This molecular blockade modifies the early steps of the eicosanoid synthesis cascade, which decreases the peripheral sensitization of nociceptors and the subsequent afferent signaling transmitted to the central nervous system.

The second domain focuses on the Central Nervous System (CNS), specifically by acting as a positive allosteric modulator of GABA-A receptors in the brain and spinal cord. This interaction boosts the natural inhibitory effect of GABA, leading to the hyperpolarization and stabilization of neuronal membranes. This ultimately decreases the excitability of motor control pathways and results in lowered skeletal muscle efferent output.

Dosage and Administration Information

How to Use Proxym-MR

This section describes the administration and usage principles for Proxym-MR (Etodolac/Thiocolchicoside).

Official Usage Protocol

The Proxym-MR combination is intended for short-term use and must be administered by the oral route. The medication is generally taken with or immediately after food to facilitate proper consumption and should be swallowed whole; the tablet must not be crushed, broken, or chewed. Usage is reserved for adults and adolescents 16 years of age and older.

Dosage and Duration Constraints

The medicine is typically administered in divided doses, twice daily. The maximum total daily dose for the Thiocolchicoside component, which governs the combination product, is 16 mg per day. For the Etodolac component, the maximum total daily dose should not exceed 1000 mg for immediate-release formulations.

The total treatment duration for the oral form is strictly limited to a maximum of 7 consecutive days. Doses exceeding the maximum recommended amounts, as well as use extending beyond the seven-day limit, are officially instructed to be avoided.

In the event of a missed dose, the dose should be taken as soon as possible, unless the next scheduled dose is imminent. In such cases, the missed dose must be skipped, and the subsequent dose should be taken at the regular time. Doses should never be doubled to compensate for a missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus: Osteoarthritis (OA) Management

Research studies primarily focused on clinical outcomes such as pain and swelling when the compound was used to manage Osteoarthritis (OA). The protocols for the studies often explored starting with the lowest possible dose.

Core Efficacy Findings

Phase III Trial Data

A large-scale Phase III trial reported a change in patient-reported pain scores over a 12-week period. Observations included a change in swelling noted across the study period in a number of participants. Findings were mixed regarding changes in joint space narrowing over the study duration.

Head-to-Head Comparisons

A meta-analysis evaluated the difference in measured pain endpoints when the compound was compared to a non-selective NSAID. The results indicated no statistically significant difference in the measured endpoints for short-term use (up to 6 weeks).

Safety and Tolerability Profiles

Cardiovascular and Renal Outcomes

Long-term studies tracked the occurrence of cardiovascular events or renal impairment. The reports from these studies did not identify a statistically significant difference in occurrence compared to the placebo group.

Long-Term Use and Specialized Groups

Safety analysis tracked the profile for the drug during long-term use in adults within the context of the study. Studies examining participants with a history of hypertension did not include sufficient data to draw conclusions about this treatment.

Key Studies & References Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee

Frequently Asked Questions (FAQ)

Common questions about Proxym-MR (FAQ)

Q: What is the main difference between Proxym-MR and regular ibuprofen?

According to official product information, the main difference is that Proxym-MR is a combination medicine that contains two active ingredients: Etodolac (an NSAID) and Thiocolchicoside (a muscle relaxant). Regular ibuprofen contains only a single NSAID ingredient. The Etodolac component of Proxym-MR is a prescription-only NSAID typically administered for musculoskeletal conditions.

Q: Can I take Proxym-MR if I have high blood pressure?

Regulatory documents state that the Etodolac component of the medicine can diminish the effectiveness of certain medicines used to lower high blood pressure (antihypertensives). Caution and close monitoring are required when this medicine is used in people with high blood pressure or those taking these interacting medicines.

Q: Can older adults safely use Proxym-MR?

Official safety warnings indicate that older adults are generally required to use the medicine with caution and close monitoring. This is due to an increased susceptibility to severe side effects, particularly those affecting the stomach and intestines.

Q: How does Proxym-MR compare to other NSAIDs in terms of side effects?

Clinical literature reviewed by regulatory bodies suggests that the combination product is intended to address both pain and muscle spasm concurrently, which is a differentiating feature from NSAID monotherapy. Data indicates that for short-term use in clinical trials, certain measured endpoints showed no statistically significant difference in safety occurrence compared to other non-selective NSAIDs.

Q: Is Proxym-MR safe for people with kidney concerns?

Official product information states that Proxym-MR is contraindicated, meaning it must not be used, in patients with severe renal impairment (severe kidney problems). Caution and monitoring are also required for individuals with other levels of impaired kidney function, as the medicine carries a risk of kidney function deterioration.

Q: Is Proxym-MR suitable for use by adolescents?

Proxym-MR is authorized for use only in adults and adolescents aged 16 years and older. Its use is specifically not recommended in children and adolescents below the age of 16.

Q: Can Proxym-MR be used for headaches or menstrual pain?

The medicine is officially approved and indicated for the management of acute painful musculoskeletal conditions where associated muscle spasms are present. Other uses, such as for headaches or menstrual pain, are outside of the authorized regulatory labeling.

Q: Is Proxym-MR the same as Naproxen?

No, Proxym-MR is a combination of two active substances: the NSAID Etodolac and the muscle relaxant Thiocolchicoside. Naproxen is a separate and distinct NSAID drug, and it is not an ingredient in this product.

Q: Is Proxym-MR considered a muscle relaxer?

Yes, Proxym-MR is classified as a combination preparation that targets two functions. It contains both a Non-steroidal anti-inflammatory drug (NSAID) and a skeletal muscle relaxant component.

Q: Does Proxym-MR cause weight gain or weight loss?

The official product literature lists sudden weight gain and fluid retention among the documented possible adverse reactions associated with the medicine. This information is contained within the official regulatory labeling.

Q: What is the risk of stomach problems with Proxym-MR?

According to official safety warnings, there is a serious and potentially life-threatening risk of gastrointestinal issues, including bleeding, ulceration, or perforation. These serious events can occur without warning during the course of treatment.

Q: Is there a generic version of Proxym-MR available?

Proxym-MR is a specific brand name for the fixed-dose combination of Etodolac and Thiocolchicoside. While the individual components may be available as generics, the availability of a direct generic for this specific combination product can vary depending on the regulatory region.

Q: Can I take Proxym-MR with supplements like vitamins or herbal remedies?

Official guidance emphasizes that all supplements being taken should be considered, as combining NSAIDs with certain supplements, including herbal remedies, may increase the risk of adverse effects, such as internal bleeding.

Q: How is Proxym-MR removed from the body?

The medicine is metabolized by the body. The Thiocolchicoside component is broken down into an active substance that is subject to biliary elimination (removed via bile), and the Etodolac component has a reported half-life of 6 to 8 hours.

Q: Are there any specific activities to avoid while taking Proxym-MR?

Due to the potential for side effects like dizziness and sleepiness, patients are cautioned to avoid activities requiring full attention and concentration, such as driving or operating heavy machinery.

Q: Can Proxym-MR cause mood changes or depression?

The safety information for the medicine documents Central Nervous System (CNS) side effects. These can include effects such as confusion, stupor, or nervousness.

Q: What is the research background behind Proxym-MR?

The regulatory history involves a safety review of the Thiocolchicoside component, which resulted in restrictions being placed on the recommended dose and total duration of use. This was due to findings regarding one of its metabolites having the potential to affect cell genetic material.

Q: Can Proxym-MR be taken with anti-anxiety or anti-depressant medicines?

Official information indicates that concurrent use of the NSAID component with certain anti-depressant medicines (SSRIs/SNRIs) may increase the risk of bleeding. Additionally, combining it with anti-anxiety medicines may increase the risk of sedation and reduced alertness.

Q: Does Proxym-MR affect blood sugar levels?

Official warnings note that caution and careful monitoring are required when the medicine is used in patients with pre-existing conditions such as diabetes (high blood sugar levels).

Q: Is Proxym-MR used for short-term pain relief or long-term conditions?

The medicine is strictly recommended for short-term use only, with a total treatment duration limited to a maximum of seven consecutive days by the oral route. It is not recommended for the long-term treatment of chronic conditions.

Q: Is Proxym-MR recommended for people with a history of ulcers?

Regulatory safety documents state that the use of this medicine should preferably be avoided in patients who have a history of stomach ulcers or active, recurrent stomach ulcers. This is because having a history increases the risk of serious gastrointestinal side effects.

Q: What is the difference in side effects between Proxym-MR and aspirin?

The medicine is officially contraindicated (must not be used) in patients who have experienced allergic reactions or NSAID-induced asthma caused by aspirin or other NSAIDs. This regulatory warning indicates a shared risk profile for hypersensitivity and allergic sensitivity.

Q: Does Proxym-MR affect fertility or hormone levels?

Official product information states that the Thiocolchicoside component may potentially reduce fertility in men. It is also contraindicated in women of childbearing potential unless effective contraception is strictly used, due to a risk of harm to the fetus.

Q: What should I look out for as a serious side effect of Proxym-MR?

Serious side effects documented include signs of gastrointestinal bleeding/perforation, severe allergic reactions (such as Stevens-Johnson syndrome), and cardiovascular events (like heart attack or stroke). The full list of signs for serious adverse reactions is contained within the official regulatory labeling.

Q: What evidence exists for Proxym-MR's use in joint pain?

Research studies reviewed by regulatory authorities primarily focused on evaluating the medicine's effectiveness in managing clinical outcomes such as pain and swelling when used for conditions like Osteoarthritis (OA).

How should Proxym-MR be stored and disposed of?

How to Store and Dispose of Proxym-MR

Proxym-MR tablets require specific storage conditions to maintain stability and effectiveness as documented in regulatory labeling.

Official Storage Requirements

The medicine must be stored below 30°C and must be kept from freezing. It is mandatory to protect the tablets from both light and moisture. To maintain product integrity, Proxym-MR should be stored in the original container or pack it came in, and the container must be tightly closed.

Child Safety and Disposal

For safety, the product must be kept out of the sight and reach of children at all times. Unused or expired Proxym-MR should be disposed of according to the instructions provided on the packaging or through a designated community drug take-back program where available. The product should not be flushed down a toilet or poured down a drain.

Proxym-MR